In the past week, LYEL stock has gone down by -14.61%, with a monthly gain of 18.35% and a quarterly plunge of -16.52%. The volatility ratio for the week is 19.70%, and the volatility levels for the last 30 days are 12.36% for Lyell Immunopharma Inc The simple moving average for the last 20 days is 2.55% for LYEL stock, with a simple moving average of -21.92% for the last 200 days.

Is It Worth Investing in Lyell Immunopharma Inc (NASDAQ: LYEL) Right Now?

Additionally, the 36-month beta value for LYEL is -0.83. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”

Elon Musk just Triggered a BOOM in These Stocks

Something strange is happening in the stock market…. This select group of stocks are going absolutely bananas. And it's all because of Elon Musk. Get your copy of "Top 5 Tech Stocks to Buy in 2024"

Click Here to Download the FREE Report.


The average price predicted by analysts for LYEL is $6.50, which is $4.63 above the current price. The public float for LYEL is 121.97M and currently, short sellers hold a 15.74% ratio of that float. The average trading volume of LYEL on November 17, 2023 was 833.10K shares.

LYEL) stock’s latest price update

The stock of Lyell Immunopharma Inc (NASDAQ: LYEL) has decreased by -8.78 when compared to last closing price of 2.05. Despite this, the company has experienced a -14.61% fall in its stock price over the last five trading sessions. Seeking Alpha reported 2023-11-10 that Lyell Immunopharma results from a phase 1 study using LYL797 for the treatment of relapsed/refractory NSCLC and TNBC patients with ROR1 expression expected in the 1st half of 2024. Results from phase 1 study using LYL845 for the treatment of patients with relapsed/refractory metastatic or advanced melanoma, NSCLC, and colorectal cancer are expected in 2024. Lyell Immunopharma is advancing a 2nd generation CAR-T known as LYL119 and an IND submission for it is expected in 1st half of 2024. It is also advancing a second-generation TIL.

Analysts’ Opinion of LYEL

Many brokerage firms have already submitted their reports for LYEL stocks, with JP Morgan repeating the rating for LYEL by listing it as a “Neutral.” The predicted price for LYEL in the upcoming period, according to JP Morgan is $5 based on the research report published on August 28, 2023 of the current year 2023.

LYEL Trading at 11.16% from the 50-Day Moving Average

After a stumble in the market that brought LYEL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.61% of loss for the given period.

Volatility was left at 12.36%, however, over the last 30 days, the volatility rate increased by 19.70%, as shares surge +18.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.59% lower at present.

During the last 5 trading sessions, LYEL fell by -14.61%, which changed the moving average for the period of 200-days by -42.99% in comparison to the 20-day moving average, which settled at $1.84. In addition, Lyell Immunopharma Inc saw -46.11% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at LYEL starting from Klausner Richard, who sale 58,020 shares at the price of $2.28 back on Aug 15. After this action, Klausner Richard now owns 930,880 shares of Lyell Immunopharma Inc, valued at $132,286 using the latest closing price.

Stock Fundamentals for LYEL

Current profitability levels for the company are sitting at:

The net margin for Lyell Immunopharma Inc stands at -216.24. The total capital return value is set at -20.21, while invested capital returns managed to touch -19.35. Equity return is now at value -25.05, with -21.45 for asset returns.

Based on Lyell Immunopharma Inc (LYEL), the company’s capital structure generated 8.13 points at debt to equity in total, while total debt to capital is 7.51. Total debt to assets is 7.22, with long-term debt to equity ratio resting at 7.58. Finally, the long-term debt to capital ratio is 7.01.

When we switch over and look at the enterprise to sales, we see a ratio of -1.16, with the company’s debt to enterprise value settled at 0.24. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.59.


In conclusion, Lyell Immunopharma Inc (LYEL) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.